Lipfendra is an oral medication taken once daily. When used alongside a balanced diet and regular physical activity, it helps lower LDL ("bad") cholesterol, a major risk factor for cardiovascular disease.

The medicine also expands treatment options for adults whose condition requires additional intervention alongside a healthy lifestyle, in line with evidence-based medical practice, and supports improvements in the quality of pharmaceutical care.

With this approval, the UAE has become the second country in the world to authorise the treatment, reflecting the efficiency of its regulatory system and its commitment to accelerating patients' access to innovative medicines.

The Emirates Drug Establishment urged the public, particularly those with high cholesterol, to maintain a healthy lifestyle that includes a balanced diet and regular physical activity, and to consult a healthcare professional to assess their condition and determine the most appropriate treatment, thereby helping to reduce the risk of cardiovascular disease and promote overall health.